Belite Bio (NASDAQ: BLTE) CSO details stock options and share stakes
Rhea-AI Filing Summary
Belite Bio, Inc. filed an initial insider ownership report for Chief Scientific Officer Nathan L. Mata, detailing his existing equity holdings. The filing shows stock options to purchase 123,066 ordinary shares at an exercise price of $6.0000 per share, expiring on April 17, 2032, which had fully vested before March 18, 2026. It also lists options on 100,000 ordinary shares at $14.4500 per share expiring on July 16, 2033, and 100,000 ordinary shares at $48.4600 per share expiring on August 28, 2034, both subject to monthly vesting schedules tied to continued service. In addition, he directly holds 16,666 American depositary shares and 16,666 ordinary shares, with each ADS representing one ordinary share.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | American depositary share | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
Footnotes (1)
- Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer. The option to purchase 123,066 ordinary shares had vested prior to March 18, 2026. The option shall vest (i) as to 50,000 ordinary shares on July 17, 2023, and (ii) as to 50,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following July 17, 2023, subject to continued service to the Issuer on each such date. The option shall vest as to 100,000 ordinary shares in 36 equal and continue monthly installments for each full month of services completed following August 29, 2024, subject to continued service to the Issuer on such date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
